用於治療代謝症候群之醫藥組成物农业专利-农业学术服务平台

发明人:: SOMMERFELD, MARK,索墨费德　马克,索墨費德　馬克,SCHAEFER, HANS-LUDWIG,史崔佛　汉斯路维格,史崔佛　漢斯路維格,BOSCHEINEN, OLIVER,波崔内　奥利维,波崔內　奧利維,HABERMANN, PAUL,哈伯曼　保罗,哈伯曼　保羅,RAO, ERCOLE,罗欧　艾克力,羅歐　艾克力,DREYER, MATTHIAS,德耶　马提斯,德耶　馬提斯,索墨费德马克,索墨費德馬克,史崔佛汉斯路维格,史崔佛漢斯路維格,波崔内奥利维,波崔內奧利維,哈伯曼保罗,哈伯曼保羅,罗欧艾克力,羅歐艾克力,德耶马提斯,德耶馬提斯

摘要：: The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.本發明係關於一種含有至少一種FGF-21(纖維母細胞生長因子21)化合物、至少一GLP-1R(類升糖素肽-1受體)激動劑以及選擇性地至少一抗糖尿病藥物和/或至少一DPP-4(二肽基肽酶-4)抑制劑的醫藥組成物供用於治療至少一代謝症候群和/或動脈粥樣硬化，特別是糖尿病、異常血脂症、肥胖和/或脂肪過多。